The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
The odds of shepherding a new drug to market in recent years has fallen to nearly one in 10 — about half of the previous rate, according to a new study released this week. First, a new treatment must survive several layers of …
French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, t…
What is preventing the French pharmaceutical group and U.S. biotech from reaching a merger agreement?
Continue reading Still No Deal Between Sanofi-Aventis and Genzyme
Still No Deal Between Sanof…
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs — those that address unmet medical needs — based on fewer trials than usual. But it turns out that…